New England Compounding Center's (NECC) - Fungal Meningitis Outbreak

Posted Monday, October 22, 2012

Due to numerous reports of Fungal Meningitis associated with the use of contaminated injectable corticosteroid products (methylprednisolone acetate and triamcinolone acetonide) compounded and distributed by New England Compounding Center?s (NECC) Framingham, Massachusetts pharmacy, the Food and Drug Administration warned medical providers NOT to use any NECC compounded preparations. To eliminate any misinformation and confusion, CuraScript SD Specialty Distribution wants to inform healthcare professionals that all drug products including injectable drug products are purchased from properly registered FDA manufacturers. At NO time, did CuraScript SD Specialty Distribution have a contract with, purchased or distribute any compounded preparations from New England Compounding Centers. The drug products distributed by CuraScript SD Specialty Distribution are not involved in any way with the contaminated corticosteroid products prepared by and distributed by NECC. All drug products are purchased from registered FDA manufacturers who adhere to the requirements of Good Manufacturing requirements.

Read More

RECALL: Contaminated Preservative Free Methylprednisolone Acetate (80mg/ml)

Posted Wednesday, October 10, 2012

As it has been reported, The New England Compounding Center (NECC) has voluntarily expanded its recall to include all products currently in circulation that were compounded at and distributed from its facility in Framingham, MA. Please rest assured that CuraScript SD does not source its products from compounding pharmacies. Products distributed by CuraScript SD have not been affected by this recall. For more information about the this recall or about Fungal Meningitis visit the Centers for Disease Control and Prevention site at: http://www.cdc.gov/HAI/outbreaks/meningitis.html Regards, CuraScript Specialty Distribution

Read More

Important Safety Information Regarding Carpuject Syringe System? Potential Overfill

Posted Friday, May 18, 2012

Hospira is issuing this Important Safety Information letter to alert Healthcare Professionals to the potential overfill of volume amounts in the pre-filled Carpuject syringe system. This also includes the 2 mL iSecure presentations of midazolam and ondansetron. Hospira has received reports of Carpuject syringes containing more than the labeled fill volume of medication than is stated on the label. See attached for list of affected products and lots.

Read More

HOSPIRA ANNOUNCES IMPORTANT SAFETY INFORMATION REGARDING CARPUJECT SYRINGE SYSTEM AND THE POTENTIAL FOR OVERFILL

Posted Friday, May 18, 2012

HOSPIRA ANNOUNCES IMPORTANT SAFETY INFORMATION REGARDING CARPUJECT SYRINGE SYSTEM AND THE POTENTIAL FOR OVERFILL -- Company requests healthcare professionals visually inspect and confirm the fill volume prior to administration -- LAKE FOREST, Ill., May 18, 2012 ? Hospira, Inc. (NYSE: HSP) announced today that it is notifying healthcare professionals regarding the potential for overfill in the pre-filled Carpuject? Syringe System, as some syringes may contain more medication than is stated on the label. The notice applies to Carpuject syringes and the 2mL iSecure? presentations of midazolam and ondansetron within expiration, which includes the following 15 drugs, all of which were manufactured between June 2010 and February 2012.

Read More

Important Announcement Regarding Your C2 Orders

Posted Thursday, March 1, 2012

Avoid Rejection of Your DEA 222 Form In order to continue to provide you the superior customer service you have come to expect, please be advised that all DEA 222 forms must be completed following the guidelines and regulations requested by the DEA. This includes properly filling in the full legal name of the distributor on your form. Effective April 1, 2012 when ordering class II narcotics; CuraScript SD Specialty Distribution must be entered in the supplier field. All other variations such as CuraScript, CuraScript SD will result in an automatic rejection of the form. We look forward to facilitating your ordering process further which is why we are excited to announce the current development of an online controlled substance ordering system (CSOS) that is expected to be available later this year. Thank you for using CuraScript SD Specialty Distribution for your pharmaceutical and supply needs. Sincerely, The CuraScript SD Specialty Distribution Customer Service Team

Read More

New Rolling Terms Coming Soon

Posted Thursday, November 10, 2011

Nov. 10, 2011 - In an effort to expand our revenue cycle management and pricing options to accounts, CuraScript Specialty Distribution (CuraScript SD) will begin offering new payment terms on certain products. These new rolling terms will provide additional saving options and will replace the current ?flex? program on orders placed on or after Nov. 12, 2011. It will not affect standard account terms, other prompt pay terms on your account or orders placed prior to Nov. 12.

Read More

BENLYSTA J CODE NOW ASSIGNED

Posted Tuesday, November 1, 2011

The Centers for Medicare & Medicaid Services (CMS) has assigned a J code to BENLYSTA, which will apply to dates of service on or after January 1, 2012. The code is: J0490, INJECTION, BELIMUMAB, 10 MG. For more information, visit the CMS website at: https://www.cms.gov/MedHCPCSGenInfo.

Read More

Archive


Media Relations

Connect With Us

Quick Links

Learn more about your best price on our full line of products!
Request a Quote